A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine
Abstract
Despite increased reports of amphetamine abuse and dependence, a putative pharmacotherapy has yet to be identified. In a previous study from our laboratory, 20 mg aripiprazole, an atypical antipsychotic that has partial agonist activity at D(2) receptors, attenuated many of the behavioral effects of d-amphetamine. Aripiprazole (20 mg) also impaired performance on a computerized version of the DSST when administered alone, indicating that the attenuation observed may have been functional as opposed to receptor mediated. The present experiment was conducted to determine whether a lower dose of aripiprazole (10 mg) could acutely attenuate the discriminative-stimulus, subject-rated, and physiological effects of d-amphetamine (2.5-15 mg) without impairing performance as measured with a computerized version of the DSST. The results of the present experiment indicate that 10 mg aripiprazole attenuated some abuse-related behavioral effects of d-amphetamine and was generally devoid of effects, including significant performance impairment, when administered alone. These findings suggest that 10 mg aripiprazole would be a reasonable starting dose for the treatment of stimulant abuse and dependence. Future research should examine the effects of chronic aripiprazole administration in combination with methamphetamine or cocaine.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Risperidone has shown promise for the treatment of methamphetamine abuse, and aripiprazole is a promising treatment for amphetamine abuse.
“Finally, risperidone, a D2-receptor antagonist, has shown promise for the treatment of methamphetamine abuse [182], and aripiprizole, a partial D2 agonist is a promising treatment for amphetamine abuse [183].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [183]
Cites
Burris, K. D., Molski, T. F. P., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 924 · see citing works
Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence
Volkow, N. D., Chang, L. L., Wang, G., Fowler, J. S., Franceschi, D., Sedler, M. J., Gatley, S. J., Miller, E. N., HITZEMANN, R. J., Ding, Y., et al. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09414.2001 · Cited by 754 · see citing works
Volkow, N. D., Wang, G.-J., Fowler, J., Logan, J., Gatley, S., Wong, C., Hitzemann, R., & Pappas, N. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35115-8 · Cited by 434 · see citing works
Weiss, F., Markou, A., Lorang, M. T., & Koob, G. F. (1992) · Brain Research · doi:10.1016/0006-8993(92)91327-b · Cited by 318 · see citing works
Medications development: Successes and challenges
Vocci, F. J., & Ling, W. W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.010 · Cited by 161 · see citing works
Risperidone for the Treatment of Cocaine Dependence: Randomized, Double-Blind Trial
Grabowski, J. G., Rhoades, H. M., Silverman, P. B., Schmitz, J. M., Stotts, A. L., Creson, D., & Bailey, R. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00003 · Cited by 116 · see citing works
Rush, C. R., Kollins, S. H., & Pazzaglia, P. J. (1998) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.6.1.32 · Cited by 108 · see citing works
Self-citationRisperidone Attenuates the Discriminative-Stimulus Effects of d-Amphetamine in Humans
Rush, C. R., Stoops, W. W., Hays, L. R., Glaser, P. E. A., & Hays, L. R. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048439 · Cited by 86 · see citing works
Self-citationA pilot trial of olanzapine for the treatment of cocaine dependence
Kampman, K. M., Pettinati, H. M., Lynch, K. G., Sparkman, T., & O’Brien, C. P. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00009-7 · Cited by 83 · see citing works
Lile, J. A., Stoops, W. W., Vansickel, A. R., Glaser, P. E. A., Hays, L. R., & Rush, C. R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300803 · Cited by 76 · see citing works
Self-citationDopamine receptor partial agonists could address the duality of cocaine craving
Childress, A. R., & O’Brien, C. P. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01422-4 · Cited by 62 · see citing works
Alprazolam Attenuates the Behavioral Effects of d-Amphetamine in Humans
Rush, C. R., Stoops, W. W., Wagner, F. P., Hays, L. R., & Glaser, P. E. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000130553.55630.ad · Cited by 50 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.016 · Cited by 432 · see citing works
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299 · see citing works
“Finally, risperidone, a D2-receptor antagonist, has shown promise for the treatment of methamphetamine abuse [182], and aripiprizole, a partial D2 agonist is a promising treatment for amphetamine abuse [183].”
BackgroundPharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242 · see citing works
Approaches to the development of medications for the treatment of methamphetamine dependence
Vocci, F. J., & Appel, N. M. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01772.x · Cited by 114 · see citing works
Martinotti, G., Nicola, M. D., Giannantonio, M. D., & Janiri, L. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089596 · Cited by 102 · see citing works
Treatments for Methamphetamine Abuse
Brackins, T., Brahm, N. C., & Kissack, J. C. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011426557 · Cited by 93 · see citing works
“Limitations of this study included the acute aripiprazole administration which differs from clinical research settings where aripiprazole is dosed chronically in clinical practice, the small sample size, the complex medication regimen, and large number of sessions which could have ‘‘taught’’ the subjects how to answer…”
BackgroundLeite, J. V., Guimarães, F. S., & Moreira, F. A. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.09.016 · Cited by 80 · see citing works
Coffin, P. O., Santos, G., Das, M., Santos, D., Huffaker, S., Matheson, T., Gasper, J. J., Vittinghoff, E., & Colfax, G. N. (2012) · Addiction · doi:10.1111/add.12073 · Cited by 67 · see citing works
Thomsen, M., Fink‐Jensen, A., Woldbye, D. P. D., Wörtwein, G., Sager, T. N., Holm, R., Pepe, L. M., & Caine, S. B. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1245-1 · Cited by 64 · see citing works
“The present and previous studies of acute effects of aripiprazole in rodent selfadministration procedures are also in agreement with the clinical studies showing decreased subject-rated effects of amphetamine after acute aripiprazole administration (Lile et al. 2005; Stoops et al. 2006).”
Newton, T. F., Reid, M. S., Garza, R. D. L., Mahoney, J. J., Abad, A., Condos, R., Palamar, J. J., Halkitis, P. N., Mojisak, J., Anderson, A., et al. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009097 · Cited by 61 · see citing works
“The earlier studies (Lile et al., 2005; Stoops et al., 2006) included a smaller number (n=6), but they used a within-subjects design, which is statistically more powerful.”
InfluentialPharmacological Treatments for Cocaine Dependence: Is There Something New?
Karila, L., Reynaud, M., Aubin, H., Rolland, B., Guardia, D., Cottencin, O., & Benyamina, A. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796150873 · Cited by 51 · see citing works
“For example, it was suggested that 10 mg aripiprazole would be a reasonable starting dose for the treatment of stimulant abuse and dependence [118].”
BackgroundEfficacy and Safety of Aripiprazole in Alcohol Dependence
Martinotti, G., Nicola, M. D., & Janiri, L. (2007) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990701313660 · Cited by 51 · see citing works
“Some recent studies are in line with this hypothesis, suggesting a possible effect of aripiprazole in lowering both desire for and the use of cocaine (7) and alcohol (8) in comorbid schizophrenic subjects, while Stoops et al. (9) found that 10 mg aripiprazole attenuated some abuserelated behavioral effects of d-amphet…”
BackgroundResultSulaiman, A. H., Gill, J. S., Said, M. A., Zainal, N. Z., Hussein, H. M., & Ng, C. G. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667116 · Cited by 47 · see citing works
Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice
Sørensen, G., Sager, T. N., Petersen, J. H., Brennum, L. T., Thøgersen, P., Bengtsen, C. H., Thomsen, M., Wörtwein, G., Fink‐Jensen, A., & Woldbye, D. P. D. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1069-z · Cited by 46 · see citing works
“Consistent with this concept, aripiprazole has been shown to reduce cocaine craving (Brown et al. 2005) and abuse in schizophrenic patients (Beresford et al. 2005) and to decrease subject-rated effect of d-amphetamine (Lile et al. 2005; Stoops et al. 2006).”
Stoops, W. W. (2006) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.14.4.413 · Cited by 38 · see citing works
Self-citationRepeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse
Feltenstein, M. W., Do, P. H., & See, R. E. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1671-8 · Cited by 36 · see citing works
“2007) and clinical (Beresford et al. 2005; Brown et al. 2005; Lile et al. 2005; Stoops et al. 2006) data indicates that DA partial agonist compounds such as aripiprazole may be effective therapeutic agents for preventing relapse in abstinent cocaine users.”
InfluentialAripiprazole for Relapse Prevention and Craving in Alcohol-Dependent Subjects
Janiri, L., Martinotti, G., & Nicola, M. D. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318150c841 · Cited by 36 · see citing works
Sevak, R. J., Vansickel, A. R., Stoops, W. W., Glaser, P. E. A., Hays, L. R., & Rush, C. R. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318221b2db · Cited by 35 · see citing works
Self-citationLile, J. A., Kelly, T. H., Pinsky, D. J., & Hays, L. R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1393-3 · Cited by 32 · see citing works
“…which subjects learn to discriminate between a Drug condition (i.e., 25 mg Δ9-THC) and a Not Drug condition (i.e., placebo; e.g., Babalonis et al. 2008; Griffiths et al. 1990; Heishman and Henningfield 1991; Lile et al. 2004, 2005a, b, 2006, 2007; Stoops et al. 2005, 2006; Rush et al. 2000, 2003).”
Self-citationMoran, L. M., Phillips, K. A., Kowalczyk, W. J., Ghitza, U. E., Agage, D. A., Epstein, D. H., & Preston, K. L. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000268 · Cited by 32 · see citing works
“…administered aripiprazole in non-treatment-seeking misusers of D-amphetamine or methamphetamine: acute aripiprazole reduced amphetamine’s discriminative-stimulus effects (Lile et al., 2005), positive subjective effects (Stoops et al., 2006), and rates of self-administration (Stoops et al., 2013).”
Jerlhag, E. (2008) · Alcohol · doi:10.1016/j.alcohol.2007.11.004 · Cited by 31 · see citing works
Bergman, J. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0014398 · Cited by 31 · see citing works
Stoops, W. W., Lile, J. A., Lofwall, M. R., & Rush, C. R. (2007) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990701651556 · Cited by 29 · see citing works
“The dose of aripiprazole was selected because results of previous research indicates that 10 mg may be the lowest effective dose in terms of altering the behavioral effects of stimulants (6).”
BackgroundMethodSelf-citationLile, J. A., Stoops, W. W., Glaser, P. E. A., Hays, L. R., & Rush, C. R. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110385597 · Cited by 27 · see citing works
“…dosing procedures have demonstrated an attenuation of the effects of d-amphetamine in non-drug-dependent individuals (Lile et al., 2005; Stoops et al., 2006), whereas studies of repeated aripiprazole administration in dependent subjects have found enhanced effects for stimulants that…”
BackgroundResultInfluentialSelf-citationAripiprazole and Ropinirole Treatment for Cocaine Dependence: Evidence from a Pilot Study
Meini, M., Moncini, M., Cecconi, D., Cellesi, V., Biasci, L., Simoni, G., Ameglio, M., Pellegrini, M., Forgione, R. N., & Rucci, P. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796150783 · Cited by 27 · see citing works
“The results of the present study indicate that aripiprazole and ropinirole are safe in patients with cocaine dependence at the study dosages of 5-10 mg per day and 0.75-1.5 mg per day, in line with the literature [37] [45].”
BackgroundResultInfluentialHuman drug discrimination: A primer and methodological review.
Bolin, B. L., Alcorn, J. L., Reynolds, A. R., Lile, J. A., & Rush, C. R. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000077 · Cited by 27 · see citing works
Self-citationSimilar discriminative-stimulus effects of d-amphetamine in women and men
Vansickel, A. R., Lile, J. A., Stoops, W. W., & Rush, C. R. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.05.003 · Cited by 24 · see citing works
“A modified progressiveratio procedure, for example, has recently been shown to be sensitive to individual differences in humans (Stoops et al., 2006b).”
BackgroundMethodSelf-citationMavrikaki, M., Nomikos, G. G., & Panagis, G. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709991143 · Cited by 24 · see citing works
“2008) and the subject-rated effects of Amph in humans (Lile et al. 2005 ; Stoops et al. 2006).”
BackgroundLile, J. A., Stoops, W. W., Hays, L. R., & Rush, C. R. (2008) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802308262 · Cited by 21 · see citing works
“Given that 10 mg of aripiprazole appears to be the lower threshold of effective doses to alter the effects of stimulants such as cocaine and d-amphetamine (3, 20), aripiprazole might have a narrow therapeutic window as a pharmacotherapy for stimulant-use disorders.”
BackgroundResultSelf-citationInfluence of aripiprazole pretreatment on the reinforcing effects of methamphetamine in humans
Stoops, W. W., Bennett, J. A., Lile, J. A., Sevak, R. J., & Rush, C. R. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.007 · Cited by 18 · see citing works
Self-citationLiu, Y., Sun, H., Bao, Y., Li, S., Beveridge, T. J. R., Di, X.-L., Yang, F., & Lü, L. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.10.024 · Cited by 18 · see citing works
Li, S., Zou, Y., Liu, L.-J., Wu, P., & Lü, L. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.01.014 · Cited by 17 · see citing works
Lile, J. A., Stoops, W. W., Glaser, P. E. A., Hays, L. R., & Rush, C. R. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.06.006 · Cited by 16 · see citing works
“the atypical antipsychotic aripiprazole in combination with stimulant drugs have found that acute pretreatment attenuated the discriminative-stimulus and self-reported effects of cocaine and damphetamine (Lile et al., 2005, 2010; Stoops et al., 2006), but that the reinforcing and self-reported effects of cocaine were…”
ResultSelf-citationAcupuncture for Major Depressive Disorder
Yeung, A., & Mischoulon, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1023a · Cited by 16 · see citing works
A mechanistic overview of approaches for the treatment of psychostimulant dependence
Jensen, K. L., Jensen, S. B., & Madsen, K. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.854176 · Cited by 12 · see citing works
“their drug-discriminative performance (Stoops et al., 2006).”
Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole
Bäckström, P., Etelälahti, T. J., & Hyytiä, P. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00223.x · Cited by 12 · see citing works
“In laboratory investigations with human subjects, acute aripiprazole was shown to attenuate amphetamine’s and cocaine’s discriminative stimulus and subject-rated effects without severe performance impairment (Stoops et al. 2006; Stoops et al. 2007).”
BackgroundIdentification of Treatment Targets in a Genetic Mouse Model of Voluntary Methamphetamine Drinking
Phillips, T. J., Mootz, J. R. K., & Reed, C. L. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.02.001 · Cited by 12 · see citing works
The influence of dopamine autoreceptors on temperament and addiction risk
Zald, D. H. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105456 · Cited by 9 · see citing works
Regnier, S. D., Lile, J. A., Rush, C. R., & Stoops, W. W. (2022) · Journal of the Experimental Analysis of Behavior · doi:10.1002/jeab.744 · Cited by 9 · see citing works
Self-citationRelationship between drug discrimination and ratings of subjective effects
Reynolds, A. R., Bolin, B. L., Stoops, W. W., & Rush, C. R. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e328364505f · Cited by 7 · see citing works
“Data from six previous studies that were conducted in our laboratory were included in the current retrospective analysis (Rush et al., 2003, 2004; Lile et al., 2005a, 2005b; Stoops et al., 2006; W.W. Stoops, P.E. Glaser, C.R. Rush, unpublished observation).”
BackgroundMethodSelf-citationLiu, Y., Bao, Y., Sun, H., Beveridge, T. J. R., Li, S., Di, X.-L., Yang, F., & Lü, L. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e78a2b · Cited by 6 · see citing works
“Immediate administration of both low and high doses of aripiprazole has been shown to substantially attenuate the discriminative stimulus and subjective responses to amphetamine in humans.(45,47) However, several clinical studies involving a longer period of aripiprazole treatment have reported findings that are somew…”
MethodResultAlipour, M., Jafarian, M., Sisakht, R. R., Mokri, A., Gorji, A., Zarrindast, M., Lorestani, F., & Razaghi, E. M. (2021) · European Addiction Research · doi:10.1159/000515398 · Cited by 5 · see citing works
Thurstone, C., Loh, R. M., Foreman, K., Thurstone, C., & Wolf, C. (2023) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2023.0053 · Cited by 5 · see citing works
“Similarly, human laboratory studies show that ar-ipiprazole in doses ranging from 10 to 20mg reduces the reinforcing effects of amphetamine, cocaine, and methamphetamine (Lile et al., 2011; Stoops et al., 2006).”
Arnold, K., & Yager, J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1023e · Cited by 5 · see citing works
Rush, C. R., Vansickel, A. R., & Stoops, W. W. (2011) · doi:10.1002/9781118023150.ch14 · Cited by 5 · see citing works
Self-citationReply to Sertraline Versus Venlafaxine XR in Major Depressive Disorder
Shelton, R. C. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1023d · Cited by 5 · see citing works
Repetitive administration of aripiprazole enhances locomotor response to methamphetamine in mice
Cheng, M.-C., Hsu, S.-H., & Chen, C. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.09.002 · Cited by 4 · see citing works
Sevak, R. J., Stoops, W. W., & Rush, C. R. (2010) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2010.494213 · Cited by 4 · see citing works
“Each study was designed as a pretreatment study in which d-amphetamine doses were administered alone and in combination with a single dose of an antipsychotic (12, 13, 16, 17) or a benzodiazepine (14, 15).”
MethodSelf-citationMedication Development for the Treatment of Substance Abuse
Fulton, B. S. (2008) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)00004-3 · Cited by 3 · see citing works
Reply to Acupuncture for Major Depressive Disorder
Schnyer, R. N., & Chambers, A. S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1023b · Cited by 2 · see citing works
Dwoskin, L. P., Glaser, P. E. A., & Bardo, M. T. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_52 · Cited by 1 · see citing works
Self-citationIs Aripiprazole Useful to Refrain From Cocaine Use After Detoxification (Avoiding Relapses)?
Cassano, G. B., Lattanzi, L., Litta, A., Lombardi, V., Tatulli, A., Benedetti, A., Longobardi, A., & Maremmani, I. (2009) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0b013e318195001f · Cited by 1 · see citing works
Reply to Sponsored Clinical Trials and Bias
Gelenberg, A. J., & Freeman, M. P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1023g · Cited by 1 · see citing works
Addiction to Amphetamines and Methamphetamines
Elkashef, A. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_16
Horton, D. B. (2012) · UKnowledge (University of Kentucky)
Sponsored Clinical Trials and Bias
Preda, A. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1023f
Sertraline Versus Venlafaxine XR in Major Depressive Disorder
Lusicic, A., & Jagadheesan, K. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1023c
- Authors
- Stoops, W. W., Lile, J. A., Glaser, P. E. A., & Rush, C. R.
- Affiliations
- University of Kentucky (US)
- Corresponding author
- Rush, Craig R.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 84
- Issue
- 2
- Pages
- 206-209
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2045143875
- Cited by
- 57
- References
- 12
- Citations by year
- 2023: 2 · 2022: 2 · 2021: 1 · 2016: 3 · 2014: 1 · 2013: 2 · 2012: 5
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug and Alcohol Dependence (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (R01 DA 010325, R01 DA 017711, T32 DA007304)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- aripiprazole, d-amphetamine, stimulant abuse, stimulant use disorder, discriminative stimulus effects
- MeSH terms
- Aripiprazole, Adult, Central Nervous System Stimulants, Blood Pressure, Dextroamphetamine, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Heart Rate, Humans, Male, Piperazines, Surveys and Questionnaires, Antipsychotic Agents, Quinolones, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
